BioSig to Acquire PURE BIOSCIENCE for $10.5M
Ticker: STEX · Form: 8-K · Filed: Dec 6, 2024 · CIK: 1530766
| Field | Detail |
|---|---|
| Company | Biosig Technologies, Inc. (STEX) |
| Form Type | 8-K |
| Filed Date | Dec 6, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $288,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, biosciences
TL;DR
BioSig buying PURE BIOSCIENCE for $10.5M cash/stock, closing Q1 2025.
AI Summary
BioSig Technologies, Inc. announced on December 3, 2024, that it has entered into a definitive agreement to acquire PURE BIOSCIENCE, INC. for approximately $10.5 million in cash and stock. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition could expand BioSig's product offerings and market reach in the biosciences sector, potentially leading to increased revenue and competitive positioning.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overpayment, and failure to achieve expected synergies, which could impact BioSig's financial performance.
Key Numbers
- $10.5M — Acquisition Value (Total consideration for PURE BIOSCIENCE, INC.)
Key Players & Entities
- BioSig Technologies, Inc. (company) — Registrant
- PURE BIOSCIENCE, INC. (company) — Acquisition Target
- $10.5 million (dollar_amount) — Acquisition Price
- December 3, 2024 (date) — Agreement Date
- first quarter of 2025 (date) — Expected Closing Date
FAQ
What is the primary business of PURE BIOSCIENCE, INC.?
The filing does not explicitly detail the primary business of PURE BIOSCIENCE, INC., but it is being acquired by BioSig Technologies, Inc., suggesting a strategic fit within the biosciences sector.
What is the breakdown of the $10.5 million acquisition price between cash and stock?
The filing states the acquisition is for approximately $10.5 million in cash and stock, but does not provide a specific breakdown between the two components.
Are there any specific regulatory approvals required for this acquisition?
The filing mentions 'customary closing conditions' but does not specify if particular regulatory approvals are needed beyond those typically associated with such transactions.
What is BioSig Technologies, Inc.'s strategic rationale for acquiring PURE BIOSCIENCE, INC.?
The filing implies a strategic rationale by stating the agreement is definitive, suggesting it aligns with BioSig's business objectives, though specific details on the synergy are not provided in this excerpt.
What are the key performance indicators or financial metrics that BioSig expects to improve post-acquisition?
This specific 8-K filing does not detail the expected performance improvements or key metrics BioSig anticipates from the acquisition of PURE BIOSCIENCE, INC.
Filing Stats: 458 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-12-06 09:00:15
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital M
- $288,000 — reement. Plaintiff was seeking at least $288,000 in damages. The Company believed Plaint
Filing Documents
- form8-k.htm (8-K) — 35KB
- 0001493152-24-048981.txt ( ) — 205KB
- bsgm-20241203.xsd (EX-101.SCH) — 3KB
- bsgm-20241203_lab.xml (EX-101.LAB) — 33KB
- bsgm-20241203_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOSIG TECHNOLOGIES, INC. Date: December 6, 2024 By: /s/ Anthony Amato Name: Anthony Amato Title: Chief Executive Officer